Rhabdomyolysis in a HIV-infected Patient Following the Addition of Raltegravir, A Case Report with Review of the Literature
Nov 2013 DOI 10.14302/issn.2324-7339.jcrhap-13-304
Alexandria Garavaglia WilsonCorresponding author
Antiretrovirals have traditionally been associated with much toxicity. Newer antiretrovirals are considered much less toxic relative to older antiretrovirals. Upon its FDA-approval in 2009, raltegravir’s adverse drug reaction profile was found to be similar to placebo. However, recently there have b…